| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.9 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | ETP-46464 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |